Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Toni Choueiri, MD Profile picture
@DrChoueiri
Dec 29, 2022 • 11 tweets • 21 min read • Read on X
Scrolly
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022:

Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag anyone involved

This is not an exhaustive list!

@OncoAlert @DanaFarber

#OnwardFor2023 Image
1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval.
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10… ImageImageImage
2/ In #PCa patients with detectable PSA after prostatectomy, lymph node RT + ADT+ PBRT⬆️freedom from progression compared to ADT+ PBRT and PBRT alone according to #SPPORT trial.
@_APollack @DrHowardSandler @TheLancet
thelancet.com/journals/lance… ImageImage
3/ Another @US_FDA approved triplet therapy in de novo #mCSPC: abiraterone (+ ADT + docetaxel) improves OS and radiographic PFS compared to SOC±RT in the #PEACE-1 trial with modest⬆️toxicity (mainly HTN).
#Fizazi @AlbertoBossial @GustaveRoussy @TheLancet
thelancet.com/journals/lance… ImageImage
4/ In 2 #STAMPEDE RCTs: Abiraterone (±enzalutamide) combined with ADT in high risk M0 #PCa⬆️metastasis-free survival, OS, PFS, DSS. Unclear benefit of adding enzalutamide with⬆️toxicity.
@AttardLab @Prof_Nick_James @mattsydes @TheLancet @Silke_Gillessen
thelancet.com/journals/lance… ImageImageImage
5/ IL-15 superagonist NAI can induce persistent CR in 71% of BCG-unresponsive #NMIBC with #CIS + 89% avoided cystectomy and 100% DSS at 2 years.
@UroCancerMD @UclaUrology @DrPatSoonShiong @NEJMEvidence
evidence.nejm.org/doi/full/10.10… ImageImageImage
6/ In the GETUG-AFU V05 #VESPER trial, neoadjuvant dd-MVAC for M0 #MIBC ⬆️3-year PFS compared to Gem/Cis.
@GETUG_Unicancer @JCO_ASCO
ascopubs.org/doi/full/10.12… ImageImageImage
7/ Promising data from 1L enfortumab vedotin + pembrolizumab in cis-ineligible, metastatic #urothelial cancer (EV-103): ORR 73.3%, CRR 15.6% with good tolerability. Median DOR &OS exceeding 2 years. 👀on phase 3 trial.

@DrChrisHoimes @DrRosenbergMSK @JCO_ASCO @OncologyTimes ImageImage
8/ Data from the #IMmotion010 trial: adjuvant atezolizumab unfortunately did not meet its primary endpoint of improved DFS in #RCC at high risk of recurrence after nephrectomy.
@montypal @UzzoRob #AxelBex @AlbigesL @brian_rini @crisuarez08
thelancet.com/journals/lance… ImageImageImage
9/ Promising efficacy of cabozantinib/nivolumab in the treatment of papillary, unclassified and translocation-associated #RCC with a 47.5% ORR (median PFS 12.5 mos and OS 28 mos). Limited response in chromophobe RCC.

@ChungHanLee3 @motzermd @JCO_ASCO
ascopubs.org/doi/full/10.12… ImageImage
10/ In the phase 2 #SAKK 01/10 trial, single-dose carboplatin followed by involved-node RT in stage II #seminoma showed a favorable efficacy and toxicity profile with 93.7% PFS at 3 years.
@Alex_Papachris @SAKK_ch @TheLancetOncol ImageImageImage

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Toni Choueiri, MD

Toni Choueiri, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrChoueiri

Toni Choueiri, MD Profile picture
Jan 1
HIGHEST RANKED TRIALS for 2025

TOP 10 #cancerclinicaltrials in 2025 w/MOST Impact

1/ #DeLLphi304 @NEJM led by #Zeusofoncology @g_mountzios @HenryDunantGR : In relapsed SCLC post-platinum, BiTE DLL-3 Tarlatamab improved mOS vs. Chemo (13.6 vs 8.3 m, HR 0.60). PFS and in cancer-related dyspnea also improved.

nejm.org/doi/full/10.10…Image
Image
Image
2/ Practice-changing trial, #ATOMIC in @JCO_ASCO: In dMMR stage III colon cancer, adding atezolizumab to adjuvant mFOLFOX6 improved DFS (HR 0.50!!)
@FASinicropeMD @DennisJHsu #JeffMeyerhardt -- #ASCO2025 Plenary discussed wonderfully by @MyriamChalabi @NKI_nl

ascopubs.org/doi/10.1200/JC…Image
Image
Image
3/ #SERENA6 is the first Phase III trial to use a ctDNA-guided approach to tackle endocrine resistance: In ER+/HER2– metastatic breast cancer, early switch to Camizestrant upon ctDNA-detected ESR1 mutation markedly delayed progression. PFS 16.0 vs 9.2 m (HR 0.44). QoL decline was delayed and toxicity remained low. Glad to see our own investigator-extraordinaire @elmayerm @DanaFarber 2nd author. Also #ASCO2025 Plenary

nejm.org/doi/full/10.10…Image
Image
Read 10 tweets
Toni Choueiri, MD Profile picture
Dec 24, 2025
IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU clinical trials in 2025!

1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO

nejm.org/doi/full/10.10…Image
Image
2/ Updated EV-302 (2.5-yr f/u). EV+pembro as 1L SOC in la/mUC. PFS 12.5 vs 6.3 mo (HR 0.48); OS 33.8 vs 15.9 mo (HR 0.51) vs chemo. Durable benefit with no new safety signals.
@tompowles1 @shilpaonc

annalsofoncology.org/article/S0923-…Image
Image
Image
3/ POTOMAC (Phase III): adding 1 year of durvalumab to BCG induction + maintenance In BCG-naive high-risk NMIBC significantly improved DFS vs BCG alone. 32% risk reduction for recurrence or death (HR 0.68) at ~5-yr f/u. Manageable safety profile. Supports IO + BCG as a potential new standard in high-risk NMIBC.

@tompowles1 @TheLancet @nealshore @mdesantis234 @AstraZeneca
thelancet.com/journals/lance…Image
Image
Read 10 tweets
Toni Choueiri, MD Profile picture
Jan 1, 2025
END OF YEAR TOP ALL CANCER TRIALS in 2024!

JUST in on 1 JAN 2025:

Paper 1:

#neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO @ProfCUBlankNKI

nejm.org/doi/full/10.10…Image
Image
Paper 2:

The #TRANSMET study shows liver transplantation + chemo improves 5-year survival (56.6%) vs chemo alone (12.6%) for unresectable colorectal liver metastases. A potential game-changer in colorectal liver metastases! @TheLancetOncol



@GelliMaximilia1 @CHBPaulBrousse @GustaveRoussythelancet.com/journals/lance…Image
Paper 3:

The #TOPGEAR trial in @NEJM reveals: Adding preoperative chemoradiotherapy to perioperative chemo in resectable gastric cancer doubled pathological complete responses (17% vs 8%) but did not boost overall survival.

A step forward in understanding optimal strategies for gastric cancer treatment!

nejm.org/doi/full/10.10…
@Sydney_Uni @PeterMacRadOnc @OncoAlertImage
Image
Image
Read 11 tweets
Toni Choueiri, MD Profile picture
Dec 27, 2024
IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024

1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos
⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45)
⏩ OS benefit: 31.5 vs 16.1 mo (HR= 0.47)

@tompowles1 @NEJM #ESMO2023 Plenary

nejm.org/doi/full/10.10…Image
Image
2/NIAGARA trial: Perioperative durvalumab with NAC in operable bladder cancer à EFS and OS benefit.
⏩32% reduction in risk of recurrence/death
⏩ 25% reduction in the risk of death
⏩No new safety signals.
🎯Potential new SOC for cisplatin-eligible MIBC!

#ESMO2024 Plenary

@tompowles1 again @NEJM

nejm.org/doi/full/10.10…Image
Image
3/ Keynote-564: 1st phase 3 trial to demonstrate overall survival benefit for adjuvant treatment in #RCC #Pembrolizumab

⏩38% reduced risk of recurrence/death (HR 0.62)
⏩New SOC for high-risk RCC post-nephrectomy

@NEJM with @ASCO GU 2024 Image
Image
Read 10 tweets
Toni Choueiri, MD Profile picture
Dec 26, 2023
And now, onto the Top 10 Translational GU Papers of 20-23. Again, not an exhaustive list, with some our @DanaFarber @DanaFarber_GU being involved in.

Let us start! Image
1/#RCC histological subtypes display diverse epigenetic configurations. Allelic imbalances play a role in modifying TF binding sites, especially through candidate SNPs.

Potential targets for future investigations and therapeutic strategies?

@AminNassarMD @sarahaboualaiwi @SylvanBacaLab #FreedmanLab

nature.com/articles/s4146…Image
Image
Image
2/ Unlocking metastatic secrets: 🧬A novel #RCC model created with CRISPR-Cas9 editing reveals 9p21 disruption’s role, recurrent patterns driving progression, and #INF signaling’s

@perelli_luigi @LabGenovese @NatureCancer
nature.com/articles/s4301…

Image
Image
Read 11 tweets
Toni Choueiri, MD Profile picture
Dec 24, 2023
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag

This is not an exhaustive list!

@OncoAlert @danafarber @DanaFarber_GU

#OnwardFor2024 Image
1/#COSMIC-313 phase 3 trial shows ⬆️PFS with Cabozantinib plus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic #RCC presented @myESMO #ESMO22

@motzermd @NEJM @tompowles1 @AlbigesL @DrDanielHeng @FabioSchutz78 @BurottoMauricio



COI: trial PInejm.org/doi/full/10.10…Image
2/In HRR-def #mCRPC: adding talazoparib to enza as 1L improved rPFS(HR=0.45), #PSA-progression, time to chemo, RR, could ⬆️OS (HR=0.69, immature) from Ph 3 #TALAPRO-2 trial. Presented #GU23 @ASCO

@neerajaiims @NatureMedicine #Fizazi @AzadOncology

nature.com/articles/s4159…


Image
Image
Image
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(